In an attempt to study the effect of Embelin on various human cancer cell lines, a decrease in cell viability was observed in the Embelin-treated cells, particularly the prostate cancer cells, in a dose-dependent manner without affecting the normal cells by inhibiting the Akt signaling pathway and thereby leading to apoptosis (Park et al., 2015[54]). The gene discussed is AKT1; the disease is cancer.